A Phase 3b, Single-Arm, Multicenter Open-Label Study of Venetoclax in Combination With Azacitidine or Decitabine in an Outpatient Setting in AML Patients Ineligible for Intensive Chemotherapy
Latest Information Update: 24 May 2024
At a glance
- Drugs Azacitidine (Primary) ; Azacitidine (Primary) ; Decitabine (Primary) ; Venetoclax (Primary)
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- Sponsors AbbVie
- 01 May 2024 Results for safety and efficacy, published in the Hematological Oncology
- 22 Feb 2023 Number of treatment arms have been increased from 1 to 2 by the addition of Experimental: Venetoclax 400 mg + decitabine 20 mg arm.
- 10 Jun 2022 Status changed from active, no longer recruiting to completed.